Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Microbot Medical Inc.MBOT · Entity 6767 | General Manager, CTO | February 18, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Microbot Medical Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2036-02-18 | Direct | 105,000 |
Reported balance
After 2026-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 105,000 · Balance 105,000 F1: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 21:45 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001493152-26-007610 · ownership.xml · derivative · entry 1 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock, par value $0.01 per share · 105,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 43,750 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001493152-25-005408 · ownership.xml · derivative · entry 1 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock, par value $0.01 per share · 43,750 shares Expires 2035-02-05 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 5, 2025, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| February 26, 2024 Filed Feb 7, 2025 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 8,750 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001493152-25-005408 · ownership.xml · derivative · entry 2 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock, par value $0.01 per share · 8,750 shares Expires 2034-02-26 F2 · date: Such options, granted on February 26, 2024, were performance-based options the vesting of which was subject to the satisfaction of milestones. On February 5, 2025, the Compensation Committee of the Board of Directors of the Issuer confirmed and determined that the milestones with respect to 8,750 options have been met and, accordingly, vested. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 23:41 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001493152-24-007872 · ownership.xml · derivative · entry 2 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock, par value $0.01 per share · 17,500 shares Expires 2034-02-22 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 23:41 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001493152-24-007872 · ownership.xml · derivative · entry 1 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock, par value $0.01 per share · 17,500 shares Expires 2034-02-22 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 22, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001493152-23-026631 · ownership.xml · derivative · entry 1 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock, par value $0.01 per share · 17,500 shares Expires 2033-08-01 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 13:25 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001493152-23-001822 · ownership.xml · derivative · entry 1 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock, par value $0.01 per share · 35,000 shares Expires 2033-01-17 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 17, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:30 UTC | Microbot Medical Inc. MBOT · Entity 6767 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001493152-22-002552 · ownership.xml · derivative · entry 1 Sharon Simon · CIK 0001851272 · General Manager, CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2032-01-26 F1 · derivative.exercise_date: The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 26, 2022, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.